<DOC>
	<DOC>NCT00280540</DOC>
	<brief_summary>This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg compared to a more conventional approach (therapy initiated with low-dose valsartan 80 mg).</brief_summary>
	<brief_title>Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male or female age 18 or older Diagnosed as having hypertension (mean seated systolic blood pressure ≥ 150 mm Hg but &lt; 180 mm Hg and mean seated diastolic blood pressure ≥ 90 mm Hg and &lt;110 mm Hg) Patients with severe hypertension: Systolic ≥ 180 mm Hg or Diastolic ≥ 110 mm Hg History of secondary hypertension (including primary aldosteronism, renovascular hypertension, pheochromocytoma etc.) History of myocardial infarction, stroke [e.g. cerebrovascular accident (CVA), thrombotic stroke, transient ischemic attack (TIA)], or onset of heart failure within the last 6 months. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>High blood pressure</keyword>
	<keyword>Blood pressure control</keyword>
	<keyword>Blood pressure reduction</keyword>
	<keyword>Valsartan</keyword>
</DOC>